Clinical Trial Update: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating efgartigimod in Chinese patients with primary membranous nephropathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Membranous Nephropathy | Phase 2 | Status: TERMINATED